Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy

American Journal of Transplantation

Volumn 8, Issue 3, 2008, Pages 574-585

  Kumar, M S Anil ^a   Khan, S ^a   Ranganna, K ^a   Malat, G ^a   Sustento Reodica, N ^a   Meyers, W C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

African American recipients; Early steroid withdrawal; Kidney transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHRONIC GRAFT REJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; INCIDENCE; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ATROPHY; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT;

ADULT; AFRICAN AMERICANS; BIOPSY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; PROSPECTIVE STUDIES; PROTEINURIA; STEROIDS; TREATMENT OUTCOME;

EID: 39649111291     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02099.x     Document Type: Article

References (49)

1. Murray JE, Merrill JP, Harrison JH et al. Prolonged survival of human-kidney homograft by immunosuppressive drug therapy. N Engl J Med 1963 268 : 1315 1323.
2. Diethelm AG, Sterling WA, Hartley MW, Morgan JM. Alternate-day prednisone therapy in recipients of renal allografts, risks and benefits. Arch Surg 1976 111 : 867 870.
3. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcomes. In : Cecka JM, Terasaki PI, eds. Clinical transplants. Los Angeles, CA : Tissue Typing Laboratory, 1995 : 379 394.
4. Neylon JF for the FK 506 kidney transplant study group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998 65 : 515 523.
5. Meier-Kriesc HU, Ojo AO, Leichtman AB et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000 11 : 2366 2370.
6. Horber F, Casez J, Steiger U et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994 9 : 1 9.
7. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999 33 : 829 839.
8. Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone after kidney transplantation. Ann Surg 2004 240 : 510 517.
9. Hricik DE, Knauss TC, Bodziac KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003 6 : 938 942.
10. Kumar MSA, Moritz MJ, Saeed MI et al. Avoidance of steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1 year results. Am J Transplant 2005 5 : 1976 1985.
11. Haririan A, Sillix DH, Morawski K et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 2006 6 : 2396 2402.
12. Boardman RE, Alloway RR, Alexander JW et al. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005 5 : 356 365.
13. Hricik DE, Augustine JJ, Knauss TC et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant population receiving sirolimus and tacrolimus. Transplantation 2007 83 : 277 281.
14. Anil Kumar MS, Xiao S-G, Fyfe B et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005 19 : 61 69.
15. Kumar MSA, Heifets M, Moritz MJ et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: Analysis of results at three years. Transplantation 2006 81 : 832 839.
16. Solez K, Colvin RB, Racussen LC et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 7 : 518 526.
17. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723.
18. Rush DN, Jeffery JR, Gough J et al. Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. Transplantation 1995 59 : 511 514.
19. Nankivell BL, Borrows RJ, Fung CLS et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004 78 : 242 249.
20. Choi BS, Shin MJ, Shin SJ et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten year experience at a single center. Am J Transplant 2005 5 : 1354 1360.
21. Miyagi M, Ishikawa Y, Mizuiri S et al. Significance of subclinical rejection in early allograft biopsies for chronic allograft dysfunction. Clin Transplant 2005 19 : 456 465.
22. Kumar MSA. Separate reporting of clinical acute rejection and sub clinical acute rejections in kidney transplantation. Transplantation 2006 82 : 1551 1552.
23. Taussky HH. A micrometric determination of creatinine in urine by the Jaffe reaction. J Biol Chem 1954 208 : 853 861.
24. Orsonnaeu JL, Douet P, Massoubre C et al. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin Chem 1989 35 : 2233 2236.
25. Price CP, Newall RG, Boyd JC. Use of protein: Creatinine ratio measurements on random urine samples for prediction of significant proteinuria: A systematic review. Clin Chem 2005 51 : 1577 1586.
26. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004 27 (Suppl 1 S11 S14.
27. U.S. Renal Data System USRDS 2006 Annual Data Report. Atlas of End Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD 2006.
28. Cecka JM. The UNOS scientific renal transplant registry. In : Cecka JM, Terasaki PI, eds. Clinical transplants. Los Angeles, CA : Tissue Typing Laboratory, 1995 : 1 16.
29. Gaston RS, Hudson SL, Deierhoi MH et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992 53 : 103 109.
30. Issacs RB, Nock S, Spencer C et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis 1999 34 : 706 712.
31. Ricardus JH, Withington SG, Anderson AM et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from TRIPOD trials. Lepr Rev 2003 74 : 319 327.
32. Meier-kriesche HU, Port FK, ojo AO et al. effect of waiting time on renal transplant outcome. Kidney Int 2000 58 : 1311 1317.
33. OPTN/SRTR Annual Report 1994-2003. HHS/HRSA/HSB/DOT; UNOS; Arbor Research Collaborative for Health 2004.
34. Kasiske BL, Chakkera H, Roel J. Explained and unexplained ischemic heart disease risk after transplantation. J Am Soc nephrol 2000 11 : 1735 1743.
35. Mengel M, Gwinner W, Schwarz A et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2006 7 : 356 365.
36. Hoffman FC, Hale DA, Kliener DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005 5 : 573 581.
37. Lipman ML, Shen Y, Jeffery JR et al. Immune-activation gene expression in clinically stable renal allograft biopsies: Molecular evidence for subclinical rejection. Transplantation 1998 66 : 1673 1681.
38. Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 1994 57 : 857 859.
39. Meier-Kriesche HU, Schold JD, Srinivas TR et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378 383.
40. Nankivell BJ and Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006 6 : 2006 2012.
41. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998 9 : 2129 2134.
42. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am soc Nephrol 2003 14 : 1046 1052.
43. Vincenti F, Mendez R, Curtis J et al. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation 2005 80 : 910 916.
44. Haririan A, Morawski K, Sillix DH et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005 79 : 716 21.
45. Cibrik D, Meier-Kriesche HU, Bresnahan B et al. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: A 12-month randomized trial in renal transplant recipients. Clin Transplant 2007 21 : 192 201.
46. Nankivell BJ, Borrows RJ, Fung CLS et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
47. Macdonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001 71 : 271 280.
48. Meier-kriesch HU, Schold JD, Srinivas TR et al. Sirolimus in combination with Tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with Tacrolimus. Am J transplant 2005 5 : 2273 2280.
49. Pirsch JD, Miller J, Deierhoi MH et al. For the FK 506 kidney transplant study group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997 63 : 977 983.